Search the webpage

Category: Custom R&D Projects
Animals used for research:   Mouse, Rabbit, Rat  

Experimentica’s Research & Development Division is actively developing novel in vivo models for a number of indications. Some of our current activities include the development of artificial corneas for permeability screening, development of standardized and validated readouts in novel models for diabetic retinopathy, identification of pathophysiological processes in meibomain gland dysfunction, and innovative approaches to induce demyelination of the optic nerve to mimic optic neuritis.

Utilizing state-of-the-art technology for the longitunial in vivo imaging of ocular tissues, such as spectral-domain ocular coherence tomography, fluorescein angiography and vitreofluorophometry, paired with traditional histological and molecular readout, we are able to detect early patholofical changes with unprecedented accuracy.

We look forward to an opportunity to partner with you to refine or develop almost any custom in vivo project. Over the years, we have worked with numerous pharmaceutical and biotech companies and academic institutions to either implement models previously described in the scientific literature or to develop novel models for ophthalmic disease indications.

SUMMARY

Animal species
Method of induction
Follow-up period
Route of compound administration
Read-outs
Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Experimentica's Preclinical Development Pipeline

Our Preclinical Development Pipeline allows you to take your drug candidates from mechanistic in vitro studies through preclinical pharmacology to GLP tolerability and toxicology studies.

SELECTED PUBLICATIONS

  • Ragauskas S, Kielczewski E, Vance J, Kaja S, Kalesnykas G. In vivo multimodal imaging and analysis of mouse laser-induced choroidal neovascularization model. J Vis Exp (131), e56173. DOI:10.3791/56173 (2018).
  • Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, Oksala O, Ilkka J, Laru J, Järvinen K, Hirvonen J, Peltonen L. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014 Jun 5;467(1-2):34-41.

REFERENCES

  • Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. International Journal of Pharmaceutics 2016; 511:73-78.
  • Ragauskas S, Leinonen H, Puranen J, Rönkkö S, Nymark S, Gurevicius K, Lipponen A, Kontkanen O, Puoliväli J, Tanila H, Kalesnykas G. Early Retinal Function Deficit without Prominent Morphological Changes in the R6/2 Mouse Model of Huntington’s Disease. PLoS One. 2014 Dec 3;9(12):e113317.

Leave a Comment

LATEST NEWS

Experimentica Ltd. Sponsors the 2018 SILK-Elsemay Björn Symposium

News
Experimentica Ltd. is pleased to announce its co-sponsorship and participation in this year’s SILK - Elsemay Björn Symposium. This yearly ... Read More

Check out our new publication on the mouse dry-eye disease model

An alpha1 adrenergic agonist shows preclinical efficacy in a preclinical model for dry eye syndrome ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!